A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
Clinical trial NCT04732221 · COMPLETED
Trial details
- NCT number
- NCT04732221
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-19
- Primary completion
- 2024-01-04
- Enrollment
- 168
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.